Sean M. Healey & AMG Center for ALS
Healey ALS MyMatch
Sean M. Healey & AMG Center for ALS at Mass General
165 Cambridge Street, 6th floor
Boston,
MA
02114
Explore This Program
Overview
Launched in 2025, the goal of the Healey ALS MyMatch program is to accelerate the path to new ALS therapies. ALS MyMatch is an ongoing series of patient-centric Phase 1b/2a biomarker-driven clinical trials. These trials utilize genetic and biofluid markers (biomarkers) to select participants and assess a range of investigational products, including experimental and repurposed medications, cell-based therapies, gene-targeted therapies, and devices.
ALS MyMatch trials will be conducted at multiple rapid-enrolling U.S. centers from the Northeast ALS (NEALS) Consortium. Successful ALS MyMatch investigational products may be considered for future regimens of the HEALEY ALS Platform Trial, a late phase clinical efficacy trial, or transition to standalone Phase 3 trials. This collaborative ALS MyMatch initiative is made possible through generous philanthropic support to the Sean M. Healey & AMG Center for ALS at MGH.
- Suma Babu, MBBS, MPHAt the heart of ALS MyMatch lies the value of rigor and innovation to confidently answer critical scientific questions in early stages of drug development and thoughtfully inform future therapeutic development in ALS.
Principal Investigator of Healey ALS MyMatch
Community Webinars
We are committed to an ongoing dialogue with the entire ALS community. Register to attend upcoming Healey ALS MyMatch community Q&A webinars or view previous recordings.
Webinar Recordings
June 9, 2025: NEALS Webinar – ACACIA Trial of Oral Digoxin in ALS
Suma Babu, MBBS, MPH and Brian Wainger, MD, PhD of Mass General Hospital presented information about the first Healey ALS MyMatch trial, the ACACIA Trial of Oral Digoxin in ALS, and answered questions from the audience.
Watch Recording
June 5, 2025: ALS MyMatch Discussion with Dr. Suma Babu
Suma Babu, MBBS, MPH and Sabrina Paganoni, MD, PhD of Mass General Hospital presented an overview of Healey ALS MyMatch and answered questions from the audience.
Watch Recording
Partner With Us
Healey ALS MyMatch is designed to support biomarker-driven Phase 1b/2a clinical trials in ALS. The Sean M. Healey & AMG Center for ALS is seeking applications of experimental therapies for inclusion in this clinical trial initiative on a rolling basis. ALS MyMatch trials are best suited for therapies focused on biological efficacy, target engagement, CNS penetrance, pharmacokinetics and/or dose finding. We invite investigators from both academia and industry to apply for consideration in ALS MyMatch.
Confidential Disclosure Agreements (CDAs) are executed between MGH and the institution or company before the ALS MyMatch Therapy Application Form is submitted.
Download the CDA template (Word document)
In the News
February 25, 2025: Healey & AMG Center for ALS Launches ALS MyMatch: An Early Phase Biomarker Driven Trial Program – Read the release
Support ALS MyMatch
Whether you’re looking to collaborate with the Healey Center, interested in participating in ALS MyMatch, or passionate about supporting ALS research, we look forward to partnering with you.